Hoth Therapeutics (HOTH) Projected to Post Quarterly Earnings on Wednesday

Hoth Therapeutics (NASDAQ:HOTH) is anticipated to issue its results after the market closes on Wednesday, June 3rd. Analysts expect the company to announce earnings of ($0.1378) per share for the quarter.

Hoth Therapeutics (NASDAQ:HOTH) last announced its earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03).

Hoth Therapeutics Stock Performance

Shares of Hoth Therapeutics stock opened at $0.71 on Wednesday. The company has a market capitalization of $13.55 million, a PE ratio of -0.89 and a beta of 0.57. The company has a 50-day simple moving average of $0.72 and a two-hundred day simple moving average of $0.94. Hoth Therapeutics has a one year low of $0.49 and a one year high of $2.12.

Hedge Funds Weigh In On Hoth Therapeutics

Several hedge funds have recently modified their holdings of HOTH. Geode Capital Management LLC increased its holdings in shares of Hoth Therapeutics by 8.0% during the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after acquiring an additional 9,071 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Hoth Therapeutics during the third quarter valued at about $184,000. Citadel Advisors LLC acquired a new position in shares of Hoth Therapeutics during the third quarter valued at about $232,000. Lido Advisors LLC acquired a new position in shares of Hoth Therapeutics during the third quarter valued at about $32,000. Finally, Kestra Private Wealth Services LLC acquired a new position in shares of Hoth Therapeutics during the third quarter valued at about $51,000. Institutional investors and hedge funds own 7.08% of the company’s stock.

Analysts Set New Price Targets

HOTH has been the subject of a number of recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $5.00 target price on shares of Hoth Therapeutics in a report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hoth Therapeutics in a report on Friday, April 24th. Finally, Wall Street Zen downgraded shares of Hoth Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 2nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.00.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.